推荐产品
形狀
liquid
包裝
pkg of 1 × 2.5 mL (890898C-25mg)
pkg of 2 × 4 mL (890898C-200mg)
製造商／商標名
Avanti Research™ - A Croda Brand
濃度
10 mg/mL (890898C-25mg)
25 mg/mL (890898C-200mg)
應用
advanced drug delivery
脂質類型
transfection
cationic lipids
運輸包裝
dry ice
儲存溫度
−20°C
SMILES 字串
[H]C(C[N+](C)(C)C)(OCCCCCCCC/C=C\CCCCCCCC)COCCCCCCCC/C=C\CCCCCCCC.[Cl-]
應用
DOTMA is suitable for use in the synthesis of cationic microbubble.
生化／生理作用
DOTMA is a cationic lipid used as a non-viral vector for gene therapy. It exhibits effective in vitro and in vivo gene transfection. DOTMA induces a positive charge on the liposomes and thus promotes efficient liposome - cell membrane interaction.
包裝
5 mL Clear Glass Sealed Ampule (890898C-200mg)
5 mL Clear Glass Sealed Ampule (890898C-25mg)
法律資訊
Avanti Research is a trademark of Avanti Polar Lipids, LLC
也與該產品經常一起購買
訊號詞
Danger
危險分類
Acute Tox. 3 Inhalation - Acute Tox. 4 Oral - Carc. 2 - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT RE 1 Oral - STOT SE 3
標靶器官
Liver,Kidney, Respiratory system
儲存類別代碼
6.1D - Non-combustible acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects
水污染物質分類（WGK）
WGK 3
閃點（°F）
does not flash
閃點（°C）
does not flash
其他客户在看
The use of cationic microbubbles to improve ultrasound-targeted gene delivery to the ischemic myocardium
Sun L, et al.
Biomaterials, 34(8), 2107-2116 (2013)
Yun Wu et al.
Molecular therapy. Nucleic acids, 2, e84-e84 (2013-04-18)
MicroRNA-29b (miR-29b) expression has been shown to be reduced in non-small-cell lung cancer (NSCLC) tissues. Here, we have identified the oncogene cyclin-dependent protein kinase 6 (CDK6) as a direct target of miR-29b in lung cancer. We hypothesized that in vivo
Jinhong Meng et al.
Scientific reports, 10(1), 1046-1046 (2020-01-25)
P53 mutations are responsible for drug-resistance of tumour cells which impacts on the efficacy of treatment. Alternative tumour suppressor pathways need to be explored to treat p53- deficient tumours. The E3 ubiquitin ligase, ITCH, negatively regulates the tumour suppressor protein
Jayesh A Kulkarni et al.
ACS nano, 12(5), 4787-4795 (2018-04-04)
Lipid nanoparticles (LNPs) containing short interfering RNA (LNP-siRNA) and optimized ionizable cationic lipids are now clinically validated systems for silencing disease-causing genes in hepatocytes following intravenous administration. However, the mechanism of formation and certain structural features of LNP-siRNA remain obscure.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门